AKTX Kronos AI forecast
A 30-trading-day price forecast for Akari Therapeutics plc ADS (AKTX) from Kronos AI, an open-source foundation model trained on candlestick charts.
Kronos AI's median forecast puts Akari Therapeutics plc ADS at $8.34 on 2026-12-08, −2.8% from the last close of $8.58 on 2026-10-27. Eight out of ten sampled paths end between $7.65 and $8.65, and 1 of the 8 paths finish above today's price.
Forecast path
median, with the 10–90% band of the sampled pathsOpen the interactive forecast → Full analysis of AKTX
The forecast, week by week
| Date | Median | Low (10%) | High (90%) |
|---|---|---|---|
| 2026-11-03 | $7.83 | $7.02 | $8.45 |
| 2026-11-10 | $8.15 | $7.12 | $8.96 |
| 2026-11-17 | $8.34 | $7.62 | $8.58 |
| 2026-11-24 | $8.37 | $7.88 | $8.82 |
| 2026-12-01 | $8.20 | $7.92 | $8.86 |
| 2026-12-08 | $8.34 | $7.65 | $8.65 |
What is Kronos AI?
Kronos is an open-source foundation model for financial candlesticks, pre-trained on K-line data from more than 45 exchanges. Gnzub runs it on each stock's last 120 daily bars and samples several possible futures, so the forecast is a range of outcomes rather than one confident line. It is a statistical model, not an analyst: it reads price patterns only and knows nothing about news, earnings or the business.
Questions
- What is the Kronos AI forecast for AKTX?
- Kronos AI's median forecast for AKTX is $8.34 in 30 trading days, −2.8% from the last close, with a 10–90% range of $7.65 to $8.65.
- Is the AKTX Kronos forecast a buy or sell signal?
- No. It is the output of a statistical model that reads price history only. It is not investment advice, and the range shows how uncertain the model is.
- How often is the forecast updated?
- The forecasts are regenerated regularly; this one starts from the close of 2026-10-27.
Kronos forecasts for similar companies
- LLY — Eli Lilly and Company
- JNJ — Johnson & Johnson
- ABBV — AbbVie Inc.
- MRK — Merck & Company Inc.
- NVS — Novartis AG
- AZN — AstraZeneca PLC